Recent investigations on retatrutides, a dual stimulant for GLP-1 and glucose-dependent insulinotropic polypeptide, demonstrate encouraging results in addressing weight gain and type 2 diabetes. Preliminary evidence from clinical experiments reveal notable reductions in body bulk and improved glu